Blazing a New Trail

Trishula Therapeutics is dedicated to improving outcomes for people with cancer.

About Us

Our Science

Our focus is on developing transformational cancer medicines by targeting the mechanisms of immune evasion in the tumor microenvironment. TTX-030, a novel, first-in-class antibody, has been studied in two Phase 1/1b clinical studies in multiple solid tumors and now undergoing a randomized Phase 2 study in frontline metastatic pancreatic cancer.

Learn More